Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.

Breast cancer research : BCR - 3 Aug 2021

Garay Joseph P, Smith Rebecca, Devlin Kaylyn, Hollern Daniel P, Liby Tiera, Liu Moqing, Boddapati Shanta, Watson Spencer S, Esch Amanda, Zheng Ting, Thompson Wallace, Babcock Darcie, Kwon Sunjong, Chin Koei, Heiser Laura, Gray Joe W, Korkola James E

Abstract excerpt

BACKGROUND: HER2-amplified breast cancer is a clinically defined subtype of breast cancer for which there are multiple viable targeted therapies. Resistance to these targeted therapies is a common problem, but the mechanisms by which resistance occurs remain incompletely defined. One mechanism that has been proposed is through mutation of genes in the PI3-kinase pathway. Intracellular signaling from the HER2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Lapatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neuregulin-1

Share to Phosphatidylinositol Phosphates

Share to Protein Domains

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 34344439
DOI: 10.1186/s13058-021-01457-0
PMCID: PMC8336338

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.PMID 34344439Read ↗

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.Semantic proximity Read ↗

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancerSemantic proximity Read ↗

A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.Semantic proximity Read ↗

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerSemantic proximity Read ↗

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.Semantic proximity Read ↗

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.Semantic proximity Read ↗

PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.Semantic proximity Read ↗

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesSemantic proximity Read ↗

Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.Semantic proximity Read ↗

The PIK3CA gene as a mutated target for cancer therapy.Semantic proximity Read ↗

Genomic dissection and mutation-specific target discovery for breast cancer PIK3CA hotspot mutations.Semantic proximity Read ↗

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.